skip to main content

BRCA1 Multi-cancer Risk — SCE Medical Oncology MCQ

Instant feedback + full explanation. One question, done properly.

HardGynaecological CancersBRCA1 Multi-cancer RiskSCE Medical Oncology

A patient with FIGO IV high-grade serous ovarian cancer is BRCA wild type and HRD negative. She has a complete response to first-line carboplatin-paclitaxel. Bevacizumab was contraindicated because of a recent arterial thrombotic event. Which maintenance option is explicitly available under NICE TA1055 if all commercial conditions are met?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: D — Rucaparib maintenance under the BRCA-negative, bevacizumab-unsuitable pathway

Option D is correct: TA1055 includes BRCA-negative, HRD-negative or unknown disease after first-line platinum response when bevacizumab is not an option. Option B is reasonable only if maintenance is declined or unsuitable. Option C is an HRD-positive pathway and includes contraindicated bevacizumab. Option E requires a BRCA-defined pathway, and option A is governed by a separate first-line induction restriction.

Reference: NICE TA1055: first-line rucaparib maintenance in ovarian cancer. https://www.nice.org.uk/guidance/ta1055/chapter/1-Recommendations